

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 November 2001 (08.11.2001)

PCT

(10) International Publication Number
WO 01/83022 A1

(51) International Patent Classification⁷: **A61M 37/00**

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(21) International Application Number: **PCT/US01/40582**

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date: 24 April 2001 (24.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/560,213 28 April 2000 (28.04.2000) US

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


(71) Applicant (*for all designated States except US*): SOLI-DOSÉ, L.L.C. [US/US]; Suite 300, 6520 N. Western, Oklahoma City, OK 73116 (US).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): HANSEN, Richard, D. [US/US]; Suite 300, 6520 N. Western, Oklahoma City, OK 73116 (US).

(74) Agent: SEASE, Edmund, J.; Zarley, McKee, Thomte, Voorhees & Sease, Suite 3200, 801 Grand Avenue, Des Moines, IA 50309-2721 (US).

(54) Title: PACKAGING AND METHOD FOR SOLID DOSE ADMINISTRATION OF MEDICAMENTS



01/83022 A1

(57) Abstract: A method and packaging for vaccinating or medicating an animal by implanting a solid dose medicament in an animal. The solid dose medicament, or plurality of such medicaments, are each color-coded to identify a particular active ingredient,

TITLE: PACKAGING AND METHOD FOR SOLID DOSE
ADMINISTRATION OF MEDICAMENTS

FIELD OF THE INVENTION

5 This invention relates to inoculation of living animals, usually livestock or wildlife, with biologically active solid dose pellets. They may be administered subcutaneously as implants, or ballistically as a projectile.

BACKGROUND OF THE INVENTION

10 Pellet implant systems which administer hormonal medicaments subcutaneously are known. Typically, they use a dosing gun to administer a series of pharmaceutical pellet implants, usually to the ear of an animal to provide sustained release of medicament. A dosing gun or implanter usually incorporates pellet magazines containing multiple doses of pharmaceutical 15 pellets which are inserted subcutaneously into the ear tissue with an associated injection needle. The magazine channels are loaded with a series of identical pharmaceutical pellets for administration at the same injection site.

20 Implant technology, that is to say, procedures involving subcutaneous implants of pharmaceuticals and medical devices, are now well accepted and widespread in the areas of animal health and production enhancement.

25 Growth stimulants are commonly used to enhance the body weight of animals which are raised for slaughtering, such as cattle, swine, sheep, turkeys, chickens and the like. A medicament in the pellet is normally formulated for continuous sustained absorption of the active ingredients over an extended period of time.

30 Solid dose ballistic projectiles shaped for penetrating the epidermal layer of living animal tissue are also known. These are typically fired remotely, using an airgun. They lodge totally within the tissues of the animal for later release of biologically-active medicaments into the animal tissue. They have an advantage over typical hand-held implant apparatus using a needle in that the inoculated animal need not be "captured".

This invention may be used with either type of solid dose administration, but has been found particularly useful with hand-held implant administration, more particularly where combined dosing of a plurality of biologically active materials is achieved with a single needle-inserted,
5 subcutaneous implantation. For details of such implant systems, see my previous patent, U.S. Patent 5,665,363, issued September 9, 1997, and as well, other prior patents on pellet implant systems, such as U.S. Patent 5,874,098, issued February 23, 1999. Disclosures of each of these are incorporated herein by reference.

10 Particularly, when animals are multiply dosed, it is necessary for the medicament administrator to keep track of medicaments, and of which animals have in fact been dosed. This can be particularly bothersome when multiple dosing of a medicament occurs with a single subcutaneous implant, or shot, in the case of a ballistic implant. This invention has as its objective a
15 new method, packaging and system for keeping track of and systematically administering a plurality of medicaments to animals so that the operator, or medicament administrator, can be confident that all desired medicaments have in fact been administered.

20 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a front view of a bovine head, showing the ears.

Figure 2 is a back view of a bovine head for illustrative purposes, showing the subcutaneous biological ear implant site.

Figure 3 is a side view of a solid dosing implanter.

25 Figure 4 shows a typical pellet magazine in perspective.

Figure 5 shows a pellet magazine which is transparent, showing how the pellets are arranged in a prearranged multiple dosing order.

Figure 6 shows how the prearranged dosing order for the pellets can be color-coded.

SUMMARY OF THE INVENTION

A method and packaging for vaccinating or medicating an animal by implanting a solid dose medicament in an animal. The solid dose medicament, or plurality of such medicaments, are each color-coded to identify a particular active ingredient, then packaged in a pellet magazine through which the doses are visible, and thereafter the pellets are implanted, usually subcutaneously into the base of the ear or in the neck of an animal. The same system can be used for colored implants administered ballistically.

10 DESCRIPTION OF THE PREFERRED EMBODIMENT

While the description here is given as a preferred embodiment of the invention, it is to be understood that the invention is not limited to preferred embodiment. Rather, the invention is limited only by the defining limits of the claims, as opposed to any statements in the specification relating to the 15 preferred embodiment.

A calf 10 is indicated for illustrative purposes of showing the working of the medicament implant system. A suitable solid dosing implanter 12 of known construction can be used. Such devices generally include a housing 14 with a pistol grip 16, a trigger 18, and a subcutaneous implant needle. The 20 pellet implant magazine 22 is inserted into the implanter apparatus 12, and moves downwardly therethrough as trigger 18 is pulled, unloading its biological or pharmaceutical dose through a needle as trigger 18 is pulled. This action forces the multiple doses through the bore of the needle (not depicted) attached to the implant apparatus 12, and into a subcutaneous 25 puncture, particularly in the base of the ear 24 as illustrated at 26, Figure 2, or in the neck. For details of such a method, see my earlier patent 5,665,363.

Pellet magazine 22 is illustrated in perspective in Figure 4 and in Figure 3 as it would enter from the top and exit below the implanter apparatus 12. It can be seen that pellet magazine is made of an inert, see-through 30 polymeric plastic material. The magazine 22 used with implanter 12 typically contains multiple, parallel-aligned, pellet dosing columns or chambers 28. As

illustrated, the chambers are generally of such a construction that each has a hollow internal core. The chambers 28 are in side-by-side parallel relation, as illustrated.

Each chamber 28 is loaded with a plurality of discrete dosing pellets in 5 columnar relationship, as illustrated in Figure 5 at 30. Individual pellets in similar stacked relationship are shown in Figure 6. The individual pellets 32 are composed of an identified biologically active ingredient in conjunction with one or more excipients formed as part of a polymeric base release system such as described in my earlier U.S. Patent 5,665,363. Each of the solid dose pellets 10 32 include a wide range of biologically active medicaments. Indeed, the particular medicament used for pellet 32 is not a limitation on the invention. For example, the medicaments may be hormones, minerals, vitamins, antibiotics, antigens, antibodies, tranquilizers, dewormers, etc.

Preferably, the biologically active pellet comprises about 2% to 70% by 15 weight of a medicament. More preferably, the biologically active pellet comprises about 3% to 50% by weight of the medicament, most preferably about 4% to 20% by weight.

Typically, the dried powder mixture is blended with a lubricant and pelletized into final form. Lubricants facilitate the release of the pellets from 20 the pelleting dies.

A list of lubricants that can be used in the practice of the invention includes, but should not be limited to, magnesium stearate, calcium stearate, sodium stearyl fumarate, stearic acid, sodium lauryl sulfonate, polyoxyethylene (carbowaxes), polyethylene glycols, glycerol behenate, 25 hydrogenated vegetable oils and mixtures thereof. Preferably, the lubricant contains calcium stearate.

Generally, the biologically active pellet comprises an effective pellet-forming amount of a lubricant. Preferably, the biologically active pellet comprises about 0.2% to 5% by weight of a lubricant. More preferably, the 30 biologically active pellet comprises about 0.5% to 3.5% by weight of a lubricant, most preferably about 1.0% to 2% by weight.

TABLE 1

% By Weight of the
Biologically Active Pellet

		Working Range	Preferred Range	Most Preferred Range
5				
10	Biologically Active Material	2%-70%	3%-50%	4%-20%
	Excipients	balance	balance	balance
	Lubricant	0.2%-5%	0.5%-3.5%	1%-2%

Optionally, the biologically active pellet can comprise additional excipients. These additional excipients can be added to the biologically active pellet to provide increased strength, to control dissolution rates, to improve powder handling, e.g., flow and the like, or to improve the efficacy of the product. A list of additional excipients that can be used as the biologically active pellet of the invention includes, but should not be limited to:

15 precipitated or fumed silicas, sodium starch glycolates, calcium phosphate, calcium carbonate, dextrins, polyvinyl pyrrolidone, hydroxypropylcellulose, hydroxypropylmethylcellulose, polylactic acid, polyglycolic acid, magnesium aluminum silicates, microcrystalline cellulose, sodium carboxymethylcellulose and mixtures thereof. Preferably, these additional excipients are less than

20 about 50% by weight of the biologically active pellet. More preferably, these additional excipients constitute less than about 40% by weight of the biologically active pellet, most preferably 25% by weight.

25

Pellets may be generally prepared as follows:

A liquid suspension containing, for example, bacterial cells and associated products adsorbed on aluminum hydroxide gel is mixed with sufficient mannitol to yield a final weight of 15 milligrams per dose of product. The suspension is dispensed into containers, frozen, and the water removed under vacuum. After freeze drying is complete, the dried powder is harvested. The powder is processed to reduce the particle size to less than 0.1 millimeter,

and sufficient calcium stearate (approximately 1% by weight) is added for lubrication.

The powder blend is then tabletted on a conventional tabletting machine to produce uniform pellets. A typical formulation for the above pellets would
5 be:

Freeze-dried powder 15	(Powder has 10 parts bacterial
Calcium stearate 2	antigen and 5 parts mannitol)
Precipitated silica 0.5	
10 Filler, balance	

Pellets produced as above may, if desired, be converted to delayed release pellets by coating with materials that will delay the escape of the
15 medicament to the body. Materials that are useful for this are compounds that will slowly degrade or dissolve in the body fluids. Examples of materials suitable for use are hydrolytically unstable polymers such as polylactic acid, polymers such as ethylvinyl acetate that are slow to dissolve in body fluids, or waxy solids, such as cholesterol, that have a limited solubility in aqueous
20 fluids. These materials can be applied to the tablet as coatings and will act to delay the release of the active ingredient from the pellet.

There are a number of coating techniques available for adding the delayed release coatings to the pellets. Rotating drum coaters or fluidized bed coating processes can be used. Any process that can apply a uniform coating in
25 a controlled manner can be used. The thickness of the coating and water solubility will determine the delay before the product is released.

The biologically active pellets of the invention can be formed into any possible shape that the pelletizing machine is capable of making. Preferably, the shape and size of the biologically active pellet is one suitable for
30 implanting into the animal. More preferably, the shape of the biologically active pellet is such that it can be used in conjunction with an implant gun.

Most preferably, the shape and size of the pellet is adapted for implanting the biologically active pellet subcutaneously into an ear or neck of the animal.

In general, the size of the biologically active pellet depends on the dose to be administered to the animal and compatibility with the implant gun and
5 needle used.

The biologically active pellets of the invention can be implanted into any animal which is capable of responding to the biologically active material.

Generally, these animals include, but should not be limited to, cattle, hogs,
horses, cats, dogs, sheep, goats, for example. In a preferred embodiment of the
10 invention, the animal is domestic cattle.

The biologically active pellet can be subcutaneously implanted into any area of the animal which allows the biologically active pellet to come into contact with tissue fluids. Preferably, the biologically active pellet is implanted into an area of the animal which minimizes or eliminates lasting
15 damage to edible tissue of the animal. More preferably, the biologically active pellet is implanted into an ear, the neck, the tail-head or flank areas of the animal, thereby reducing potential damage to edible tissue. Most preferably, the biologically active pellet is implanted into the ear of cattle, thereby eliminating damage to edible tissue.

20 In our earlier patent, I found that implanting the biologically active pellet into an ear of the animal does not result in an undesirable "drooped ear", or "down ear" in the animal. As with any product administered through the skin, sanitary methods must be followed to reduce the likelihood of injection site infections/abscesses which may result in undesirable local tissue reactions.

25 The plurality of medicaments, if used, may be arranged in any predetermined order. One may arbitrarily select colors to represent each medicament pellet in the stack. For example, one vaccine could be represented by yellow, a second vaccine by blue, a third vaccine by white, a bacterin by green, and a second bacterin by red. These would be stacked in the order
30 shown in Figure 6 so that looking through the columns 30 in Figure 5 one would see in this order from top to bottom yellow, blue, white, green, red. In

all customer literature accompanying the dosing pellet magazine 28, the same color scheme would be consistently used throughout the description which accompanies the medicaments.

While the description herein has been given particularly with hand-held
5 implant dosing, ballistic implants can be used of the type disclosed in my co-pending application simultaneously filed herewith entitled "MEDICAMENT DOSING BALLISTIC IMPLANT OF IMPROVED ACCURACY", Serial No. _____.

If a similar color scheme is used with various medicaments, the implant casing itself could incorporate the color scheme as opposed to the
10 payload. In like manner, the packaging could use consistent representations with regard to color being coordinated with specific medicaments. Such a ballistic implant would usually only contain a single medicament. Thus, for example, if an implant casing were yellow, one would know it contained a certain vaccine; if it were blue, one would know it contained another vaccine;
15 red a certain bacterin; and so forth.

Use of the colorants is nonlimiting, but generally they would include FD&C colorants known to be non-harmful to the animals to be vaccinated, substantially inert to the administered biologically active material, and leave no persistent tissue discoloration.

20 The following were tested and found "non-viricidal" to the principal cattle modified live viruses (MLV) one might include in cattle vaccines. These include: Infectious Bovine Rhinotracheitis (IBR) Virus, Bovine Virus Diarrhea (BVD) Virus, Parainfluenza 3 (PI-3) Virus and Bovine Respiratory Syncytial Virus (BRSV); FD&C Red #40 aluminum lake pigment, FD&C Blue #1 aluminum lake pigment, FD&C Yellow #5 aluminum lake pigment.
25

These pigments in pellets were also found to leave no visible residues in the subcutaneous tissue of rabbits. Pellets containing FD&C Red #40 left no visible residues in cattle. FD&C Blue #1 and FD&C Yellow #5 have not been tested in cattle to date.

30 The FD&C Red #40 was accepted as satisfactory by the USDA-CVB (Center for Veterinary Biologics) and the FSIS (Food Safety and Inspection

Service). Application will be made shortly to the CVB for acceptance of FD&C Blue #1 and FD&C Yellow #5 based on the data gathered.

It is likely the above actually tested list could be expanded to include other 21 CFR listed FD&C and D&C aluminum lake pigments, as well as 5 other colorants (e.g., iron oxides, phenol red). Those next likely candidates include: FD&C Yellow #6 aluminum lake pigment, FD&C Red #40Y, FD&C Blue #2.

Color candidates may also be used in combination to create other colors (e.g., green).

10 The list of medicaments includes only veterinary products approved to be administered by the parenteral route. Generally, the products could include antigens related to: Vaccines (Live or Killed Virus), Bacterins and Bacterial Extracts (Killed organisms), Bacterin-Toxoids (Killed organisms + modified toxins), Toxoids (Modified toxins devoid of killed bacterial cells), and 15 antibodies related to: Antisera (Serum containing antibodies against an infectious organism). Pharmaceuticals could also be used.

In practice, products could be prepared for all domestic and wild species. Specifically, products could include antigens or antibodies related to the following for cattle: Infectious Bovine Rhinotracheitis (IBR) virus, Bovine 20 Virus Diarrhea (BVD) virus, Parainfluenza 3 (PI3) virus, Bovine Respiratory Syncytial Virus (BRSV), *Haemophilus*, *Pasteurella*, *Leptospira*, *Clostridium*, *Campylobacter*, *Corynebacterium*, *Escherichia*, *Moraxella*, *Salmonella*, *Actinomyces*, Anaplasmosis, Anthrax, *Brucella*, Coronavirus, Rotavirus, 25 *Staphylococcus*, *Trichomonas*, *Fusobacterium*.

For dogs, the following could be used: Distemper, Measles, Adenovirus, Parainfluenza, *Leptospira*, *Bordetella*, Parvovirus, Coronavirus, *Borrelia*, Rabies, *Salmonella*.

For horses, the following could be used: Anthrax, *Escherichia*, *Ehrlichia*, Encephalomyelitis, Influenza, Rabies, Rhinopneumonitis, 30 *Salmonella*, Tetanus, Viral Arteritis.

For cats, the following could be used: Rhinotracheitis, Calicivirus, Panleukopenia, Leukemia, Rabies, Infectious Peritonitis, *Microsporum*.

For sheep, the following could be used: *Clostridium*, *Corynebacterium*, *Escherichia*, *Pasteurella*, *Salmonella*, Anthrax, *Bacteroides*, Bluetongue,
5 *Campylobacter*, *Chlamydia*, Ecthyma, Epididymitis, Rabies, Tetanus.

For swine, the following could be used: Anthrax, *Bordetella*,
Clostridium, *Corynebacterium*, *Escherichia*, Encephalomyocarditis, *Erysipelas*,
Actinobacillus, *Haemophilus*, *Leptospira*, *Mycoplasma*, *Pasteurella*, PRRS,
Influenza, Parvovirus, Pseudorabies, Rotavirus, Tetanus, *Salmonella*,
10 *Streptococcus*, *Servulina*, Transmissible Gastroenteritis.

For avian, the following could be used: Bronchitis, Bursal Disease,
Mycoplasma, Newcastle Disease, *Pasteurella*, Reovirus, *Bordetella*, Coccidiosis,
Escherichia, Encephalomyelitis, *Erysipelas*, Fowl Pox, *Haemophilus*,
Adenovirus, Herpesvirus, Influenza, Laryngotracheitis, Pacheco Disease,
15 Paramyxovirus, *Salmonella*.

In addition, as earlier explained, the pellets, besides including the active which may be an antigen as above-described, and the colorant, they may contain other materials known in the tableting art. They may include fillers (inert), and fillers which are functional. Inert fillers include the following:
20 Lactose, Mannitol, Dextrose, Fructose, Sucrose, Galactose, Maltose, Sorbitol, Dextran, Dextrin, Calcium carbonate, Calcium sulfate, Dicalcium phosphate. Functional fillers include the following: Alginic acid, Various celluloses (Hydroxypropyl cellulose (HPC), Hydroxypropyl methylcellulose (HPMC), Oxidized cellulose (OC), Microcrystalline cellulose (MCC), Ethyl
25 cellulose (EC), Hydroxyethyl cellulose (HEC), Methyl cellulose (MC), Carboxymethyl cellulose (CMC), Cellulose acetate (CA), Cellulose acetate butyrate (CAB), Cellulose acetate propionate (CAP), Cellulose sodium phosphate (CSP), Cellulose triacetate (CTA), Cellulose acetate phthalate (C-A-P), Hydroxypropyl methylcellulose phthalate (HPMCP), Cellulose acetate trimellitate (C-A-T), Hydroxypropyl methylcellulose acetate succinate (HPMCAS), Sodium carboxymethyl cellulose), Polyanhydrides, Polymethyl
30

merthacrylate, Polylactides, Polyglycolides, Carbomer, Gellan gum, Sodium alginate, Acrylic copolymers, Glyceryl monostearate, Zein, Cholesterol,

Agarose, Chitosan, Xanthan gum, Polyethylene glycol (PEG), Gelatin,

Povidone, Natural gum. The pellets may also contain Glidants (Flow Aids),

5 Disintegrants, Lubricants, Adjuvants, Antibiotic Preservatives, etc. Suitable Glidants include: Precipitated silica, Fumed silica. Suitable Disintegrants include: Sodium starch glycolate, Crospovidone, Croscarmellose sodium. Suitable Lubricants include: Stearic acid, Magnesium stearate, Calcium stearate, Sodium stearyl fumarate, Glyceryl monostearate, Triglyceride esters.

10 Suitable Adjuvants include: Aluminum hydroxide, Saponin, Dimethyl dioctadecyl ammonium bromide (DDA bromide), Bacterial extracts. If antibiotics are to be included, pellets may, for example, include the following: Penicillin, Streptomycin, Gentamicin, Polymyxin B, Amphotericin B, Nystatin, Tetracycline, Neomycin.

15 Preferably, the inert filler is lactose, and the functional filler hydroxypropyl cellulose (3%-30% of the pellet by weight). The glidant preferred is precipitated silica (0.5% of the pellet weight). The most satisfactory lubricant used to date would be calcium stearate at 2% of the pellet weight. Adjuvants include levels from 1%-20% of the pellet weight and 20 may be aluminum hydroxide or DDA bromide. A suitable antibiotic preservative included at a <1% of pellet weight would be gentamicin.

All of the above may also be incorporated into the payload of ballistic implants as previously explained.

What is claimed is:

1. A method of inoculating animals with a plurality of biologically active pellets comprising: providing an implant apparatus for implanting biologically active pellets in an animal which can be operably coupled to a dosing pellet magazine; said dosing pellet magazine comprising: a series of loaded dosing pellet see-through columns, each loaded with a plurality of dosing pellets, each pellet color-coded to represent a particular medicament; and thereafter, implanting the plurality of dosing pellets in an animal to be inoculated with a single injection.
2. The method of claim 1 wherein the pellets are loaded with the doses all in the same order.
- 15 3. The method of claim 1 wherein the animal selected is cattle.
4. The method of claim 1 wherein the pellet is from 3% to 30% of functional filler.
- 20 5. The method of claim 1 wherein the pellet is 0.5% by weight glidant.
6. The method of claim 1 wherein the pellet is 1%-2% lubricant.
7. The method of claim 1 wherein the pellet is from 1% to 20% adjuvant.
- 25 8. The method of claim 1 which includes the antibiotic gentamicin.
9. A dosing pellet magazine, comprising: a plurality of connected see through pellet dosing columns, each of said columns being loaded with a plurality of dosing pellets, with each pellet color-coded to represent a particular biologically active medicament.

10. The dosing pellet magazine of claim 9 wherein the pellets are loaded with the doses all in the same order.

5 11. The dosing pellet magazine of claim 9 wherein the animal selected is cattle.

12. The dosing pellet magazine of claim 9 wherein the pellet is from 3% to 30% of functional filler.

10 13. A system of packaging biologically active implants, comprising: selecting a plurality of biologically active medicaments for implant dosing; coloring each selected medicament with a unique color to represent the selected medicament; placing the medicaments in a see through pellet magazine, with the medicaments in a prearranged order; consistently using 15 the same color scheme for packaging and instructional materials used with the packaged pellet implant doses.

14. The system of claim 13 wherein the pellets are loaded with the doses all in the same order.

20

15. A method of vaccinating animals with ballistic implants, comprising: coloring the implant bullet casing a color for representing the medicament in the bullet's payload; and administering the colored bullet to the animals to be treated.

25

16. A ballistic implant comprising a bullet casing portion colored to represent a medicament selected, in combination with a solid dose payload carrying the selected medicament represented by the color of the bullet casing.

1/2




FIG. 1




FIG. 2




FIG. 3

2/2




FIG. 4




FIG. 5




FIG. 6

INTERNATIONAL SEARCH REPORT

onial Application No

PCT/US 01/40582

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61M37/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61M A61K B65D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 004 565 A (GOULD III JAY W ET AL) 25 January 1977 (1977-01-25) column 4, line 47 - line 53; figures ---	9-14,16
A	US 5 874 098 A (SPURLIN STANFORD R ET AL) 23 February 1999 (1999-02-23) cited in the application column 4, line 50 -column 5, line 25; figures ---	9-14,16
X	US 4 077 406 A (SANDHAGE ELLSWORTH ROLAND ET AL) 7 March 1978 (1978-03-07) column 6, line 50 - line 56; figures ---	16
A		13

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

27 July 2001

06/08/2001

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2

Authorized officer

INTERNAL SEARCH REPORT

Information on patent family members

Application No

PCT/US 01/40582

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 4004565	A	25-01-1977	NONE		
US 5874098	A	23-02-1999	NONE		
US 4077406	A	07-03-1978			
			AR	213206 A	29-12-1978
			AU	2566077 A	07-12-1978
			BE	856026 A	23-12-1977
			BR	7703981 A	28-03-1978
			DE	2728143 A	05-01-1978
			DK	279577 A	25-12-1977
			ES	460060 A	01-10-1978
			FR	2355491 A	20-01-1978
			IT	1078478 B	08-05-1985
			JP	53007485 A	23-01-1978
			NL	7707052 A	28-12-1977
			ZA	7703231 A	26-04-1978